Endocrine Abstracts

Back ground: Hyperthyroidism is a common disorder with multiple etiologies and radioactive iodine (RAI) is the important modality to treat it. Successful treatment is determined by development of euthyroidism and / or Hypothyroidism within 6 months of radioactive iodine treatment. The aim of this study was to find out the outcome of RAI treatment and its association with factors like age, gender various etiologies of hyperthyroidism and baseline TSH, FT4 in our population.

Methods: This retrospective case series study was conducted at Karachi institute of Radiotherapy and Nuclear Medicine’ (KIRAN) from January 2018 to June 2020. A total of 199 participants with complete data were recruited in study after IRB approval. Demographic details, age, gender, underlying cause of hyperthyroidism (graves disease, toxic multinodular goitre, solitary toxic nodule etc, ) were obtained from medical records along with baseline FT4 & TSH. A fixed dose of 15mci of radioactive iodine was given to all patients and TSH and FT4 were measured at 6 weeks 3, 6, and 12 months to evaluate the outcome of RAI treatment. Data was analyzed by SPSS version 20 to compute mean standard deviation and percentages.

Results: In our study 77.9% were females, 22.1% males, mean age was 41.32±0.99 years. 74.4% participants had Graves’ disease, 15% had solitary toxic nodule or toxic multinodular goiter. Post RAI TSH target was achieved earlier compared to FT4. Outcome of RAI treatment in patients with Graves’ disease and toxic nodule revealed statistically significant and early result. Females revealed significant improvement in both biochemical markers i-e TSH and FT4 compared to males. Successful treatment was noticed in 35%, 56%, 75.6%, at 6 weeks, 3, 6, 12 months respectively.